The role of Fas-mediated apoptosis in thyroid autoimmune disease

Autoimmunity

Volumn 30, Issue 4, 1999, Pages 251-264

  Borgerson, Karin L ^a   Bretz, James D ^a   Baker Jr , James R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 9220 MSRB III ^*  (United States)

Author keywords

Apoptosis; Fas; FasL; Thyroid

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; AUTOIMMUNITY; HASHIMOTO DISEASE; PATHOGENESIS; REVIEW; TARGET ORGAN;

EID: 0032821034     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939908993806     Document Type: Review

References (70)

1. C.B. Thompson, Apoptosis in the pathogenesis and treatment of disease. Science 1995; 261: 1456-1462.
2. M.J. Arends and A.U. Wyllie, Apoptosis: mechanisms and roles in pathology. International Review of Experimental Pathology 1991; 32: 223-254.
3. R.C. Duke, D.M. Ojcius and J.D. Young, Cell suicide in health and disease. Scientific American 1996; 275: 80-87.
4. A.H. Wyllie, Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-556.
5. C.A. Smith, G.T. Williams, R. Kingston, E.J. Jenkinson and J.J. Owen, Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989; 337: 181-184.
6. M. Barinaga, Is apoptosis key in Alzheimer's disease? Science 1998; 281: 1303-1304.
7. A. Ashkenazi and V.M. Dixit, Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
8. N.A. Thornberry and Y. Lazebnik, Caspases: enemies within. Science 1998; 281: 1312-1316.
9. J.P. Sheridan, S.A. Marsters, R.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin et al., Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
10. R.M. Pitti, S.A. Marsters, D.A. Lawrence, M. Roy, F.C. Kischkel, P. Dowd et al., Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
11. N. Itoh, S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima et al., The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243.
12. T. Suda, T. Takahashi, P. Golstein and S. Nagata, Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
13. M. Muzio, A.M. Chinnaiyan, F.C. Kischkel, K. O'Rourke, A. Shevchenko, J. Ni et al., FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-827.
14. F.C. Kischekel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P.H. Krammer et al., Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO Journal 1995; 14: 5579-5588.
15. G. Pan, K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni et al., The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
16. J.W. Kappler, N. Roehm and P. Marrack, T cell tolerance by clonal elimination in the thymus. Cell 1987; 49: 273-280.
17. G.J. Nossal, Negative selection of lymphocytes. Cell 1994; 76: 229-239.
18. K.M. Murphy, A.B. Heimberger and D.Y. Loh, Induction by antigen of intrathymic apoptosis of CD4+CD8+ TCRlo thymocytes in vivo. Science 1990; 250: 1720-1723.
19. W. Swat, L. Ignatowicz, H. von Boehmer and P. Kisielow, Clonal deletion of immature CD4+8+ thymocytes in suspension culture by extrathymic antigen-presenting cells. Nature 1991; 351: 150-153.
20. W. Swat, L. Ignatowicz and P. Kisielow, Detection of apoptosis of immature CD4+8+ thymocytes by flow cytometry. Journal of Immunological Methods 1991; 137: 79-87.
21. R. Watanabe-Fukunaga, C.I. Brannan, N.G. Copeland, N.A. Jenkins and S. Nagata, Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-117.
22. E.M. Tan, Autoimmunity and apoplosis [comment]. Journal of Experimental Medicine 1994; 179: 1083-1086.
23. P. L. Cohen and R.A. Eisenberg, Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annual Review of Immunology 1991; 9: 243-269.
24. D.H. Lynch, M.L. Watson, M.R. Alderson, P.R. Baum, R.E. Miller, T. Tough et al., The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994; 1: 131-136.
25. F. Ramsdell, M.S. Seaman, R.E. Miller, T.W. Tough, M.R. Alderson and D.H. Lynch, gld/gld mice are unable to express a functional ligand for Fas. European Journal of Immunology 1994; 24: 928-933.
26. K.B. Elkon, Apoptosis and autoimmunity. Journal of Rheumatology 1997; 24: 6-7.
27. J.D. Mountz, J. Wu, J. Cheng and T. Zhou, Autoimmune disease. A problem of defective apoptosis. Arthritis and Rheumatism 1994; 37: 1415-1420.
28. T. Hunig and A. Schimpl, Systemic autoimmune disease as a consequence of defective lymphocyte death. Current Opinion in Immunology 1997; 9: 826-830.
29. C. Benoist and D. Mathis, Cell death mediators in autoimmune diabetes-no shortage of suspects. Cell 1997; 89: 1-3.
30. R. De Maria and R. Testi, Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunology Today 1998; 19: 121-125.
31. L.J. Hammond, M.W. Lowdell, P.G. Cerrano, A.W. Goode, G.F. Bottazzo and R. Mirakian, Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. Journal of Pathology 1997; 182: 138-144.
32. I. Okayasu, M. Saegusa, M. Fujiwara, Y. Hara and N.R. Rose, Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma. Journal of Cancer Research and Clinical Oncology 1995; 121: 746-752.
33. T. Kotani, Y. Aratake, K. Hirai, Y. Fukazawa, H. Sato and S. Ohtaki, Apoptosis in thyroid tissue from patients with Hashimolo's thyroiditis. Autoimmunity 1995; 20: 231-236.
34. C. Tanimoto, S. Hirakawa, H. Kawasaki, N. Hayakawa and Z. Ota, Apoptosis in thyroid diseases: a histochemical study. Endocrine Journal 1995; 42: 193-201.
35. N. Mitsiades, V. Poulaki, V. Kotoula, G. Mastorakos, S. Tseleni-Balafouta, D.A. Koutras et al., Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. Journal of Clinical Endocrinology and Metabolism 1998; 83: 2199-2203.
36. G.F. Del Prete, D. Vercelli, A. Tiri, E. Maggi, S. Mariotti, A. Pinchera et al., In vivo activated cytotoxic T cells in the thyroid infiltrate of patients with Hashimoto's thyroiditis. Clinical and Experimental Immunology 1986; 65: 140-147.
37. W.A. MacKenzie, A.E. Schwartz, E.W. Friedman and T.F. Davies, Intrathyroidal T cell clones from patients with autoimmune thyroid disease. Journal of Clinical Endocrinology and Metabolism 1987; 64: 818-824.
38. G. Stassi, M. Todaro, F. Bucchieri, A. Stoppacciaro, F. Farina, G. Zummo et al., Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. Journal of Immunology 1999; 162: 263-267.
39. C. Giordano, G. Stassi, R. De Maria, M. Todaro, P. Richiusa, G. Papoff et al., Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997; 275: 960-963.
40. A. Kawakami, K. Eguchi, N. Matsuoka, M. Tsuboi, S. Urayama, Y. Kawabe et al., Modulation of Fas-mediated apoptosis of human thyroid epithelial cells by IgG from patients with Graves' disease (GD) and idiopathic myxoedema. Clinical and Experimental Immunology 1997; 110: 434-439.
41. T. Suda, T. Okazaki, Y. Naito, T. Yokota, N. Arai, S. Ozaki et al., Expression of the Fas ligand in cells of T cell lineage. Journal of Immunology 1995; 154: 3806-3813.
42. G. Berke, The CTL's kiss of death. Cell 1995; 81: 9-12.
43. T.S. Griffith and T. A. Ferguson, The role of FasL-induced apoplosis in immune privilege [published erratum appears in Immunology Today 1997 Jul; 18(7): 361]. Immunology Today 1997; 18: 240-244.
44. M.W. Bennett, J. O'Connell, G.C. O'Sullivan, C. Brady, D. Roche, J. K. Collins et al., The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. Journal of Immunology 1998; 160: 5669-5775.
45. D.B. Chappell and N.P. Restifo, T cell-tumor cell: a fatal interaction? Cancer Immunology, Immunotherapy 1998; 47: 65-71.
46. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French et al., Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
47. P. Saas, P.R. Walker, M. Hahne, A.L. Quiquerez, V. Schnuriger, G. Perrin et al., Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? Journal of Clinical Investigation 1997; 99: 1173-1178.
48. A. Villunger, A. Egle, I. Marschitz, M. Kos, G. Bock, H. Ludwig et al., Constitutive expression of Fas (Apo-1/ CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90: 12-20.
49. T.A. Stokes, M. Rymaszewski, P.L. Arscott, S.H. Wang, J.D. Bretz, J.L. Bartron et al., Constituitive expression of FasL in thyrocytes. Science 1998; 279: 2015a.
50. P. Fiedler, C.E. Schaetzlein and H. Eibel, Constituitive expression of FasL in thyrocytes. Science 1998; 279: 2015a.
51. D. Smith, S. Sieg and D. Kaplan, Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. Journal of Immunology 1998; 160: 4159-4160.
52. L. Xerri, E. Devilard, J. Hassoun, C. Mawas and F. Birg, Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Molecular Pathology 1997; 50: 87-91.
53. M. Tamura, H. Kimura, T. Koji, T. Tominaga, K. Ashizawa, T. Kiriyama et al., Role of apoptosis of thyrocytes in a rat model of goiter. A possible involvement of Fas system. Endocrinology 1998; 139: 3646-3653.
54. F. Leithauser, J. Dhein, G. Mechtersheimer, K. Koretz, S. Bruderlein, C. Henne et al., Constitutive and induced expression of APO-1, a new member of the nerve growth factor tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Laboratory Investigation 1993; 69: 415-429.
55. A. Kawakami, K. Eguchi, N. Matsuoka, M. Tsuboi, Y. Kawabe, N. Ishikawa et al., Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 1996; 137: 3163-3169.
56. P.L. Arscott, J. Knapp, M. Rymaszewski, J.L. Bartron, J.D. Bretz, N.W. Thompson et al., Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor. Endocrinology 1997; 138: 5019-5027.
57. T. Suda and S. Nagata, Purification and characterization of the Fas-ligand that induces apoptosis. Journal of Experimental Medicine 1994; 179: 873-879.
58. T. Sato, S. Irie, S. Kitada and J.C. Reed, FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-415.
59. st Annual Meeting, September 16-20, 1998, Portland, Oregon.
60. D. Hockenbery, G. Nunez, C. Milliman, R.D. Schreiber and S.J. Korsmeyer, Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
61. C.L. Sentman, J.R. Shutter, D. Hockenbery, O. Kanagawa and S. J. Korsmeyer, Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-888.
62. N. Itoh, Y. Tsujimoto and S. Nagata, Effect of bcl-2 on Fas antigen-mediated cell death. Journal of Immunology 1993; 151: 621-627.
63. A. Kawahara, T. Kobayashi and S. Nagata, Inhibition of Fas-induced apoptosis by Bcl-2. Oncogent 1998; 17: 2549-2554.
64. V.K. Chiu, C.M Walsh, C.C. Liu, J.C. Reed and W.R. Clark, Bcl-2 blocks degranulation but not fas-based cell-mediated cytotoxicity. Journal of Immunology 1995; 154: 2023-2032.
65. A. Strasser, A.W. Harris, DC. Huang, P.H. Krammer and S. Cory, Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO Journal 1995; 14: 6136-6147.
66. L. Van Parijs, A. Biuckians and A.K. Abbas, Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. Journal of Immunology 1998; 160: 2065-2071.
67. C. Scaffidi, S. Fulda, A. Srinivasan, C. Friesen, F. Li, K.J. Tomaselli et al., Two CD95 (APO-1/Fas) signaling pathways. EMBO Journal 1998; 17: 1675-1687.
68. S. Hu, C. Vincenz, J. Ni, R. Gentz and V.M. Dixit, I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-95-induced apoptosis. Journal of Biological Chemistry 1997; 272: 17255-17257.
69. M. Irmler, M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner et al., Inhibition of death receptor, signals by cellular FLIP [see comments]. Nature 1997; 388: 190-195.
70. C.M. Dayan, K.A. Elsegood and R. Maile, FasL expression on epithelial cells: the Bottazzo-Feldman hypothesis revisited [see comments]. Immunology Today 1997; 18: 203.